Abstract:Genetic hearing loss is a common health problem with no effective therapy currently available. DFNA15, caused by mutations of the transcription factor POU4F3, is one of the most common forms of autosomal dominant non-syndromic deafness. In this study, we established a novel mouse model of the human DFNA15 deafness, with a Pou4f3 gene mutation (Pou4f3Δ) identical to that found in a familial case of DFNA15. The Pou4f3(Δ/+) mice suffered progressive deafness in a similar manner to the DFNA15 patients. Hair cells in the Pou4f3(Δ/+) cochlea displayed significant stereociliary and mitochondrial pathologies, with apparent loss of outer hair cells. Progression of hearing and outer hair cell loss of the Pou4f3(Δ/+) mice was significantly modified by other genetic and environmental factors. Using Pou4f3(-/+) heterozygous knockout mice, we also showed that DFNA15 is likely caused by haploinsufficiency of the Pou4f3 gene. Importantly, inhibition of retinoic acid signaling by the aldehyde dehydrogenase (Aldh) and retinoic acid receptor inhibitors promoted Pou4f3 expression in the cochlear tissue and suppressed the progression of hearing loss in the mutant mice. These data demonstrate Pou4f3 haploinsufficiency as the main underlying cause of human DFNA15 deafness and highlight the therapeutic potential of Aldh inhibitors for treatment of progressive hearing loss.More than 50% of deafness cases are due to genetic defects with no treatment available. DFNA15, caused by mutations of the transcription factor POU4F3, is one of the most common types of autosomal dominant non-syndromic deafness. Here, we established a novel mouse model with the exact Pou4f3 mutation identified in human patients. The mutant mouse display similar auditory pathophysiology as human patients and exhibit multiple hair cell abnormalities. The onset and severity of hearing loss in the mouse model is highly modifiable to environmental factors, such as aging, noise exposure or genetic backgrounds. Using a new knockout mouse model, we found Pou4f3 haploinsufficiency as the underlying mechanism of human DFNA15. Importantly, we identified Aldh inhibitor as a potent small molecule for upregulation of Pou4f3 and treatment of hearing loss in the mutant mouse. The identification of Aldh inhibitor for treatment of DFNA15 deafness represents a major advance in the unmet medical need for this common form of progressive hearing loss.

A base editor for the long-term restoration of auditory function in mice with recessive profound deafness

RNA base editing therapy cures hearing loss induced by OTOF gene mutation.

Hearing of Otof-deficient Mice Restored by Trans-Splicing of N- and C-terminal Otoferlin.

PAM-flexible Adenine Base Editing Rescues Hearing Loss in a Humanized MPZL2 Mouse Model Harboring an East Asian Founder Mutation

In vivo base editing restores sensory transduction and transiently improves auditory function in a mouse model of recessive deafness

Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor

Genetic Correction of TRMU Allele Restored the Mitochondrial Dysfunction-Induced Deficiencies in Ipscs-Derived Hair Cells of Hearing-Impaired Patients.

Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss

Gene editing in a Myo6 semi-dominant mouse model rescues auditory function

In vivo outer hair cell gene editing ameliorates progressive hearing loss in dominant-negative Kcnq4 murine model

Template-independent Genome Editing in the Pcdh15 Mouse, a Model of Human DFNB23 Nonsyndromic Deafness

Template-independent genome editing in the <i>Pcdh15<SUP>av-3j</SUP></i> mouse, a model of human DFNB23 nonsyndromic deafness

Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo

Precise Detection of CRISPR-Cas9 Editing in Hair Cells in the Treatment of Autosomal Dominant Hearing Loss

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents

AAV-Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness

Treatment of autosomal recessive hearing loss via in vivo CRISPR/Cas9-mediated optimized homology-directed repair in mice

Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation

[Study on Gene Therapy for DPOAE and ABR Threshold Changes in Adult Otof-/- Mice].

Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing

Aldh inhibitor restores auditory function in a mouse model of human deafness